| Jones Eye Clinic | |
|
4405 Hamilton Blvd, Sioux City, IA 51104-1140 | |
| (712) 239-3937 | |
| (712) 239-4946 |
| Full Name | Jones Eye Clinic |
|---|---|
| Type | Facility |
| Speciality | Ophthalmology |
| Location | 4405 Hamilton Blvd, Sioux City, Iowa |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164605192 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Secondary |
| 207W00000X | Ophthalmology | (* (Not Available)) | Primary |
| Provider Name | Jason J Jones |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1922002872 PECOS PAC ID: 1557356227 Enrollment ID: I20040420001054 |
News Archive
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
Most Americans receive health insurance coverage through their employer, or through an employed family member's dependent coverage. Yet having a job is no guarantee of coverage, according to a new policy brief from the UCLA Center for Health Policy Research.
Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.
U.S. Mills, LLC, which markets a family of healthy food brands including Uncle Sam® Cereal, announced today that the world-renowned Joslin Diabetes Center will provide educational material for U.S. Mills' Web site, www.usmillsllc.com. The content will serve as a resource to Uncle Sam Cereal consumers, many of whom live with diabetes.
› Verified 5 days ago
| Provider Name | Yian J Jones |
|---|---|
| Provider Type | Practitioner - Ophthalmology |
| Provider Identifiers | NPI Number: 1689883464 PECOS PAC ID: 5991850307 Enrollment ID: I20090909000455 |
News Archive
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
Most Americans receive health insurance coverage through their employer, or through an employed family member's dependent coverage. Yet having a job is no guarantee of coverage, according to a new policy brief from the UCLA Center for Health Policy Research.
Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.
U.S. Mills, LLC, which markets a family of healthy food brands including Uncle Sam® Cereal, announced today that the world-renowned Joslin Diabetes Center will provide educational material for U.S. Mills' Web site, www.usmillsllc.com. The content will serve as a resource to Uncle Sam Cereal consumers, many of whom live with diabetes.
› Verified 5 days ago
| Provider Name | Christopher S Diehl |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1053607515 PECOS PAC ID: 4284880659 Enrollment ID: I20120820000255 |
News Archive
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
Most Americans receive health insurance coverage through their employer, or through an employed family member's dependent coverage. Yet having a job is no guarantee of coverage, according to a new policy brief from the UCLA Center for Health Policy Research.
Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.
U.S. Mills, LLC, which markets a family of healthy food brands including Uncle Sam® Cereal, announced today that the world-renowned Joslin Diabetes Center will provide educational material for U.S. Mills' Web site, www.usmillsllc.com. The content will serve as a resource to Uncle Sam Cereal consumers, many of whom live with diabetes.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jones Eye Clinic 4405 Hamilton Blvd, Sioux City, IA 51104-1140 Ph: (712) 239-3937 | Jones Eye Clinic 4405 Hamilton Blvd, Sioux City, IA 51104-1140 Ph: (712) 239-3937 |
News Archive
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
Most Americans receive health insurance coverage through their employer, or through an employed family member's dependent coverage. Yet having a job is no guarantee of coverage, according to a new policy brief from the UCLA Center for Health Policy Research.
Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.
U.S. Mills, LLC, which markets a family of healthy food brands including Uncle Sam® Cereal, announced today that the world-renowned Joslin Diabetes Center will provide educational material for U.S. Mills' Web site, www.usmillsllc.com. The content will serve as a resource to Uncle Sam Cereal consumers, many of whom live with diabetes.
› Verified 5 days ago